The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
OBX-115, an interleukin 2 (IL2)-sparing engineered tumor-infiltrating lymphocyte (TIL) cell therapy, in patients (pts) with immune checkpoint inhibitor (ICI)-resistant unresectable or metastatic melanoma.
 
Rodabe Navroze Amaria
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex; Erasca, Inc; Iovance Biotherapeutics; Novartis; Obsidian Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); iovance Biotherapeutics (Inst); KSQ Therapeutics (Inst); Novartis (Inst); Obsidian Therapeutics (Inst); OnKure (Inst)
 
Jennifer Leigh McQuade
Honoraria - Bristol-Myers Squibb; Merck; Roche
Consulting or Advisory Role - Bristol Myer Squibb; Roche Pharma AG
Travel, Accommodations, Expenses - Merck
 
Michael A. Davies
Consulting or Advisory Role - ABM; Apexigen; Array BioPharma; Bristol-Myers Squibb; Eisai; Genentech/Roche; Iovance Biotherapeutics; NanoString Technologies; Novartis; Pfizer
Research Funding - ABM (Inst); AstraZeneca (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lead Pharma (Inst); Merck (Inst); Myriad Genetics (Inst); Oncothyreon (Inst); Pfizer (Inst); Sanofi (Inst)
 
Isabella Claudia Glitza
Honoraria - Amgen
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Leal Therapeutics; Midatech Pharma; Novartis; Sintetica
Speakers' Bureau - Array BioPharma
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst); Pfizer (Inst)
 
Steffy Jose
No Relationships to Disclose
 
Erik Norman Kraske Cressman
No Relationships to Disclose
 
Ashlynd L Clausell
No Relationships to Disclose
 
Roland L Bassett
No Relationships to Disclose
 
Sapna Pradyuman Patel
Honoraria - Emory University
Consulting or Advisory Role - Bristol Myers Squibb; Cardinal Health; Castle Biosciences; Delcath Systems; IDEAYA Biosciences; immatics; Immunocore; MSD; Novartis; OncoSec; Pfizer; Replimune; TriSalus Life Sciences
Speakers' Bureau - BMS GmbH & Co. KG; MSD
Research Funding - Bristol-Myers Squibb (Inst); Foghorn Therapeutics (Inst); IDEAYA Biosciences (Inst); InxMed (Inst); Lyvgen Biopharma (Inst); Novartis (Inst); Provectus (Inst); Seagen (Inst); Syntrix Biosystems (Inst); TriSalus Life Sciences (Inst)
Travel, Accommodations, Expenses - BMS GmbH & Co. KG; Castle Biosciences; InxMed; TriSalus Life Sciences
 
Adi Diab
Honoraria - Array BioPharma
Consulting or Advisory Role - Celgene; CureVac; CytomX Therapeutics; Idera; Memgen therapeutics; Nektar; Pfizer (Inst); Regeneron
Research Funding - Apexigen (Inst); Celgene (Inst); Idera (Inst); Lytix Biopharma (Inst); Lytix Biopharma (Inst); Nektar (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Nektar
 
Hussein A. Tawbi
Consulting or Advisory Role - Boxer Capital; Bristol-Myers Squibb; Eisai; Genentech/Roche; Iovance Biotherapeutics; Jazz Pharmaceuticals; Karyopharm Therapeutics; Medicenna; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Dragonfly Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); RAPT Therapeutics (Inst)
 
Michael K.K. Wong
Consulting or Advisory Role - Castle Biosciences; Regeneron; Replimune
 
Alexandra Ikeguchi
Research Funding - BioNTech SE (Inst); Immunocore (Inst); Merck (Inst); Regeneron (Inst)
 
Cara L Haymaker
Stock and Other Ownership Interests - Briacell
Consulting or Advisory Role - Nanobiotix
Research Funding - Avenge Bio (Inst); BTG (Inst); Dragonfly Therapeutics (Inst); Iovance Biotherapeutics (Inst); Obsidian Therapeutics (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Patent Appl No. 62/977, 672 (Inst)
 
Seoung-Ae Lee
No Relationships to Disclose
 
Madan H. Jagasia
Employment - Obsidian Therapeutics
Stock and Other Ownership Interests - Obsidian Therapeutics
Travel, Accommodations, Expenses - Obsidian Therapeutics
 
Giridharan Ramsingh
Employment - Gilead Sciences; Gilead Sciences; Obsidian Therapeutics; Obsidian Therapeutics; Obsidian Therapeutics
Stock and Other Ownership Interests - Genentech/Roche; Gilead Sciences; Obsidian Therapeutics
 
Prakash Prabhakar
Employment - Obsidian Therapeutics
Stock and Other Ownership Interests - Obsidian Therapeutics
Travel, Accommodations, Expenses - Obsidian Therapeutics
 
Raina Duan
Employment - Obsidian Therapeutics
Stock and Other Ownership Interests - Obsidian Therapeutics
Travel, Accommodations, Expenses - Obsidian Therapeutics
 
Parameswaran N Hari
Employment - Obsidian Therapeutics; Obsidian Therapeutics
Research Funding - Celgene (Inst); Millennium (Inst); Onyx (Inst); Spectrum Pharmaceuticals (Inst)